The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy
Open Access
- 10 June 2009
- journal article
- Published by Wiley in HIV Medicine
- Vol. 10 (6) , 378-387
Abstract
Objectives: The prevalence of metabolic syndrome (MS) in HIV‐infected patients on highly active antiretroviral therapy (HAART) is a subject of debate. We investigated the prevalence of MS in a cohort of Danish HIV‐infected patients and estimated the effect of the various classes of antiretroviral therapies on the prevalence of MS and its components.Methods: A cross‐sectional study was performed in which data were obtained from fasting blood tests, anthropometry, an interview questionnaire and whole‐body dual‐energy X‐ray absorptiometry (DEXA) scans. MS was defined using the National Cholesterol Education Programme (NCEP) Adult Treatment Panel (ATP) III diagnostic criteria.Results: Five hundred and sixty‐six patients were included in the study, of whom 27% were diagnosed with MS. In univariate analysis, the duration of treatment with different drug classes was associated with the prevalence of MS. In multivariate analysis, no association was demonstrated between therapeutic duration or modality and the occurrence of MS. Current nonthymidine reverse transcriptase inhibitor (NRTI) and protease inhibitor (PI) therapies were both associated with increased plasma triglycerides (TG) [odds ratio (OR) 3.42, 95% confidence interval (CI) 1.73–6.74; and OR 1.96, 95% CI 1.19–3.22, respectively].Conclusions: MS is prevalent in HIV‐infected Danes. However, treatment with specific drug classes does not seem to confer an elevated risk for MS, other than the risk conferred by known acute effects on triglycerides.Keywords
This publication has 40 references indexed in Scilit:
- Short-Term Effect of HAART on Blood Pressure in HIV-Infected IndividualsHIV Research & Clinical Practice, 2008
- Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular DiseaseJACC, 2007
- Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III CriteriaDiabetes Care, 2007
- Single‐Dose Lopinavir‐Ritonavir Acutely Inhibits Insulin‐Mediated Glucose Disposal in Healthy VolunteersClinical Infectious Diseases, 2006
- Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controlsScandinavian Journal of Infectious Diseases, 2006
- Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factorsJournal of Antimicrobial Chemotherapy, 2005
- Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a reviewScandinavian Journal of Infectious Diseases, 2004
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and LipodystrophyClinical Infectious Diseases, 2001
- HIV-1 Protease Inhibitors Induce an Increase of Triglyceride Level in HIV-Infected Men Without Modification of Insulin Sensitivity: A Longitudinal StudyHormone and Metabolic Research, 2000